Journal of Cellular Immunotherapy最新文献_第9页

CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma 靶向cd138的嵌合抗原受体修饰T细胞过继免疫治疗多发性骨髓瘤

Journal of Cellular Immunotherapy Pub Date : 2016-03-01 DOI: 10.1016/j.jocit.2014.11.001

Bo Guo , Meixia Chen , Qingwang Han , Fan Hui , Hanren Dai , Wenying Zhang , Yajing Zhang , Yao Wang , Hongli Zhu , Weidong Han

{"title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma","authors":"Bo Guo , Meixia Chen , Qingwang Han , Fan Hui , Hanren Dai , Wenying Zhang , Yajing Zhang , Yao Wang , Hongli Zhu , Weidong Han","doi":"10.1016/j.jocit.2014.11.001","DOIUrl":"https://doi.org/10.1016/j.jocit.2014.11.001","url":null,"abstract":"<div><p>Adoptive immunotherapy with T cells expressing a tumor-associated chimeric antigen receptor (CAR) provides a promising approach for tumor therapy. We designed a clinical trial for multiple myeloma (MM) treatment with CAR-modified T cells recognizing CD138 (CART-138). Five patients diagnosed with chemotherapy-refractory MM were enrolled into this trial, although one later advanced to plasma cell leukemia. By intravenous infusions, these patients received CD3<sup>+</sup> CART-138 cells in an escalating dose. No intolerable toxicity was observed during this process. CART-138 cells were expanded to a level 1000 times higher than the initial engraftment level and were maintained in the peripheral blood. In addition, increased CART-138 cells were also detected in the bone marrow. Four of the five patients had stable disease (SD) longer than three months, and one patient with advanced plasma cell leukemia had a reduction of the myeloma cells in her peripheral blood (from 10.5% to <3%). This study suggests that the treatment of CART-138 is safe, feasible, and tolerable and has potential antitumor activity in vivo, warranting further research in MM treatment using CART-138.</p></div>","PeriodicalId":100761,"journal":{"name":"Journal of Cellular Immunotherapy","volume":"2 1","pages":"Pages 28-35"},"PeriodicalIF":0.0,"publicationDate":"2016-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jocit.2014.11.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90026477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 139

A new wave: Introducing the Journal of Cellular Immunotherapy 新浪潮:《细胞免疫疗法》杂志的介绍

Journal of Cellular Immunotherapy Pub Date : 2016-03-01 DOI: 10.1016/J.JOCIT.2016.03.001

Xuetao Cao, Hu Chen

引用次数: 1

Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases 间充质干细胞:免疫调节能力及其在免疫疾病中的临床潜力

Journal of Cellular Immunotherapy Pub Date : 2016-03-01 DOI: 10.1016/j.jocit.2014.12.001

Qinjun Zhao , Hongying Ren , Zhongchao Han

{"title":"Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases","authors":"Qinjun Zhao , Hongying Ren , Zhongchao Han","doi":"10.1016/j.jocit.2014.12.001","DOIUrl":"https://doi.org/10.1016/j.jocit.2014.12.001","url":null,"abstract":"<div><p>Mesenchymal stem cells (MSCs) represent a heterogenous population of adult, fibroblast-like multi-potent cells. MSCs have drawn much attention during the last decade in the field of regenerative medicine, mainly due to their capacity to differentiate into specific cell types, abundant production of soluble growth factors and cytokines, and hematopoiesis supporting properties. In addition, MSCs can migrate to the sites of inflammation and hold potent of immunomodulatory and anti-inflammatory effects through cell and cell interactions between MSCs and lymphocytes or production of soluble factors. Therefore, the application of MSCs in many disease situations is full of possibilities for future clinical treatment. Phase III clinical trials have been run using MSCs for treatment of Graft versus Host Disease (GVHD), and MSCs product approval has been achieved for pediatric GVHD treatment in Canada and New Zealand (Prochymal<sup>®</sup>; Osiris Therapeutics). In addition, hundreds of clinical trials are being run using MSCs for treatment of several immune mediated diseases, including GVHD, aplastic anemia (AA), Crohn's disease (CD), rheumatoid arthritis (RA), and multiple sclerosis (MS). In this review we mainly focus on immunomodulation potential of MSCs and promising therapeutic application of MSCs in immune mediated diseases. Furthermore, we emphasize that biological effectiveness of MSCs will be one of most important standards to determine the dose of MSCs infusion.</p></div>","PeriodicalId":100761,"journal":{"name":"Journal of Cellular Immunotherapy","volume":"2 1","pages":"Pages 3-20"},"PeriodicalIF":0.0,"publicationDate":"2016-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jocit.2014.12.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91755100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 249

The LALF32-51 peptide as component of HPV therapeutic vaccine circumvents the alum-mediated inhibition of IL-12 and promotes a Th1 response LALF32-51肽作为HPV治疗性疫苗的组成部分绕过铝介导的IL-12抑制并促进Th1反应

Journal of Cellular Immunotherapy Pub Date : 2016-03-01 DOI: 10.1016/J.JOCIT.2015.01.001

M. Granadillo, Alain B. Alfonso, M. G. Vallespí, A. Batte, Y. Soria, E. Brown, M. Limonta, Yayrí C. Prieto, Laura A Varas, I. Torréns

引用次数: 5

Clinical efficacy and safety of stem cells in refractory Crohn's disease: A systematic review 干细胞治疗难治性克罗恩病的临床疗效和安全性:系统综述

Journal of Cellular Immunotherapy Pub Date : 2016-03-01 DOI: 10.1016/j.jocit.2016.01.001

Lei Ye , Xiaowei Wu , Na Yu , Jingxin Pan , Lianming Liao , Fangyu Wang

{"title":"Clinical efficacy and safety of stem cells in refractory Crohn's disease: A systematic review","authors":"Lei Ye , Xiaowei Wu , Na Yu , Jingxin Pan , Lianming Liao , Fangyu Wang","doi":"10.1016/j.jocit.2016.01.001","DOIUrl":"10.1016/j.jocit.2016.01.001","url":null,"abstract":"<div><h3>Background</h3><p>Refractory Crohn's disease, especially when complicated by complex perianal fistula, seriously reduces the patients' quality of life. Preclinical and clinical studies indicate stem cells may be a promising therapy for refractory Crohn's disease.</p></div><div><h3>Objective</h3><p>To systematically review evidence on clinical efficacy and safety of stem cells in refractory Crohn's disease.</p></div><div><h3>Methods</h3><p>A detailed search was performed to identify randomized controlled trials (RCT), systematic reviews of RCTs or high-quality non-RCTs published before September 2015 in the Cochrane Library, PubMed, Medline, EMBASE, and the ISI Web of Knowledge databases. Search terms included: MSC (mesenchymal stem cell), stem cells, HSC (hematopoietic stem cell), IBD (inflammatory bowel disease), CD (Crohn's disease), UC (ulcerative colitis). Two authors independently extracted data for analysis using predefined selection criteria and quality indicators. Trials were also retrieved from the website of <span>www.Clinicaltrials.gov</span><svg><path></path></svg>.</p></div><div><h3>Results</h3><p>18 of the 225 articles identified met the inclusion criteria. However, there were only two studies that had control groups. Therefore, a brief qualitative analysis of the evidence was considered to be more adequate. It seems stem cells can reduce Crohn's Disease Activity Index (CDAI) and help alleviate CD symptoms. Moreover, the incidence of serious adverse events caused by stem cell transplantation was very low (1.75%, 7/400).</p></div><div><h3>Conclusions</h3><p>Stem cell therapy for CD is very promising, but large, multicenter and randomized clinical trials are needed to further support their therapeutic benefits.</p></div>","PeriodicalId":100761,"journal":{"name":"Journal of Cellular Immunotherapy","volume":"2 1","pages":"Pages 21-27"},"PeriodicalIF":0.0,"publicationDate":"2016-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jocit.2016.01.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83365447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer in extensive stage 细胞免疫治疗作为维持治疗延长了广泛期小细胞肺癌患者的生存期

Journal of Cellular Immunotherapy Pub Date : 2016-03-01 DOI: 10.1016/j.jocit.2016.02.001

Xiao Ding , He Cao , Xiao Chen , Yuguang Zhao , Haofan Jin , Chao Niu , Kewei Ma , Ziling Liu , Jingtao Chen , Xu Wang , Lei Yang , Hua He , Wei Han , Dan Li , Huimin Tian , Wei Li , Jiuwei Cui

{"title":"Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer in extensive stage","authors":"Xiao Ding , He Cao , Xiao Chen , Yuguang Zhao , Haofan Jin , Chao Niu , Kewei Ma , Ziling Liu , Jingtao Chen , Xu Wang , Lei Yang , Hua He , Wei Han , Dan Li , Huimin Tian , Wei Li , Jiuwei Cui","doi":"10.1016/j.jocit.2016.02.001","DOIUrl":"https://doi.org/10.1016/j.jocit.2016.02.001","url":null,"abstract":"<div><h3>Background</h3><p>Small cell lung cancer (SCLC) is the most devastating type of human lung cancer. Patients usually present with disseminated disease to many organs (extensive stage). This study was to investigate the efficacy and safety of cellular immunotherapy (CIT) with autologous natural killer (NK), γδT, and cytokine-induced killer (CIK) cells as maintenance therapy for extensive-stage SCLC (ES-SCLC) patients.</p></div><div><h3>Methods</h3><p>A pilot prospective cohort study was conducted with ES-SCLC patients who had responded to initial chemotherapy. Patients received either CIT as maintenance therapy (CIT group), or no treatment (control group). Progression-free survival (PFS), overall survival (OS), and adverse effects were compared.</p></div><div><h3>Results</h3><p>Forty-nine patients were recruited in this study, with 19 patients in the CIT group and 30 patients in the control group. The patient characteristics of the 2 groups were comparable except for age, as patients in the CIT group were older than those in the control group (P < 0.05). PFS in the CIT group was superior to the control group (5 vs. 3.1 months, P = 0.020; HR, 0.489, 95% CI, 0.264–0.909, P = 0.024). OS of the CIT group was also longer than that of the control group (13.3 vs. 8.2 months, P = 0.044; HR, 0.528, 95% CI, 0.280–0.996, P = 0.048, respectively). No significant adverse reactions occurred in patients undergoing CIT.</p></div><div><h3>Conclusions</h3><p>CIT maintenance therapy in ES-SCLC prolonged survival with only minimal side effects. Integrating CIT into the current treatment may be a novel strategy for ES-SCLC patients, although further multi-center randomized trials are needed.</p></div>","PeriodicalId":100761,"journal":{"name":"Journal of Cellular Immunotherapy","volume":"2 1","pages":"Pages 36-43"},"PeriodicalIF":0.0,"publicationDate":"2016-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jocit.2016.02.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91719546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma 靶向cd138的嵌合抗原受体修饰T细胞过继免疫治疗多发性骨髓瘤

Journal of Cellular Immunotherapy Pub Date : 2016-03-01 DOI: 10.1016/J.JOCIT.2014.11.001

Bo Guo, Meixia Chen, Qing-wang Han, F. Hui, Hanren Dai, Wen-ying Zhang, Yajing Zhang, Yao Wang, Hongli Zhu, W. Han

引用次数: 144

Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases 间充质干细胞:免疫调节能力及其在免疫疾病中的临床潜力

Journal of Cellular Immunotherapy Pub Date : 2016-03-01 DOI: 10.1016/J.JOCIT.2014.12.001

Qin-jun Zhao, Hong-ying Ren, Z. Han

引用次数: 256

Editorial board members 编委会成员

Journal of Cellular Immunotherapy Pub Date : 2016-03-01 DOI: 10.1016/S2352-1775(16)30006-1

引用次数: 0

Cost-effectiveness of mammography breast cancer screening in Iranian women 伊朗妇女乳房x光检查乳腺癌的成本效益

Journal of Cellular Immunotherapy Pub Date : 2015-12-01 DOI: 10.1016/j.jocit.2015.10.041

Shahpar Haghighat , Mohammad Esmaeil Akbari , Parvin Yavari , Mehdi Javanbakht , Shahram Ghaffari

引用次数: 0